-- HealthDay staff
THURSDAY, June 16 (HealthDay News) -- The quit-smoking drug
Chantix may lead to a small but increased risk of heart problems in
people with cardiovascular disease, the U.S. Food and Drug
Administration said Thursday.
In a study of 700 smokers with cardiovascular disease who were
undergoing treatment with Chantix or a placebo, researchers saw a
small but "statistically significant" greater risk of chest pain,
non-fatal heart attacks and other cardiovascular problems in
patients taking the quit-smoking drug, the FDA said.
Details of the new findings will be shared with doctors and will
be included in the drug's medication guide to patients, the agency
In July 2009, the FDA mandated that Chantix (varenicline
tartrate) and a second smoking-cessation drug, Zyban, carry a
"black-box" warning about the potential risks of psychiatric
problems, including depression and suicidal thoughts.
In its announcement Thursday, the FDA noted that smoking is a
major contributor to cardiovascular disease, the number one killer
of Americans. So doctors and their patients should weigh the "known
benefits of Chantix against its potential risks when deciding to
use the drug in smokers with cardiovascular disease," the agency
said in a statement on its website.
Patients taking Chantix, which received FDA approval in 2006,
should contact their health-care professional if they experience
new or worsening symptoms of cardiovascular disease.
One heart expert agreed.
"In light of this study, any patient known to have cardiovascular disease who is taking Chantix or considering taking it, or health care provider considering prescribing it to a patient known to have cardiovascular disease must discuss the risks, benefits and alternatives in detail," said Dr. Jonathan Whiteson, director of the Cardiac and Pulmonary Wellness and Rehabilitation Program at NYU Langone Medical Center in New York City.
"It must be considered that there are options and that Wellbutrin has not been indicated in causing progression of cardiovascular disease in smokers with existing cardiovascular disease," Whiteson added. He said other smoking cessation aids, such as nicotine-replacement gums, patches or lozenges, as well as "adjunctive therapies such as aromatherapy, hypnosis and acupuncture" might also help smokers quit.
Whiteson stressed that the study only looked at Chantix users
who were already diagnosed with heart disease before they started
the drug, and "there is no evidence at present to suggest that
Chantix leads to the new development of cardiovascular disease in
people who are free of cardiovascular disease when they start the
The FDA said it will continue to evaluate the risks and benefits
associated with Chantix and is requiring the manufacturer -- Pfizer
Inc. -- to conduct an analysis of all previous randomized,
placebo-controlled trials of the drug. The agency said it will
release those findings to the public when they become
In a statement, Pfizer pointed out that smoking is a key risk
factor for heart disease, and quitting the habit brings heart
benefits that are "immediate and substantial," the
Wall Street Journal reported. Pfizer agreed that patients
should talk to their doctors to "determine what medications are
right for them."
For more on how to quit smoking, visit the
U.S. Centers for Disease Control and
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.